Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Knock your SOCS off!

Derek Leroith1, Peter Nissley

  • 1Diabetes Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Cancer Institute, NIH, Bethesda, Maryland 20892-1758, USA. derek@helix.nih.gov

The Journal of Clinical Investigation
|February 4, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Insulin receptor expression and its association with hyperinsulinemia in triple negative breast cancer.

Journal of the Endocrine Society·2026
Same author

Association of Race/Ethnicity with Diabetes Medication Beliefs and Self-Management Behaviors in Breast Cancer Survivors.

Journal of women's health (2002)·2025
Same author

Endocrine and metabolic alterations in response to systemic inflammation and sepsis: a review article.

Molecular medicine (Cambridge, Mass.)·2025
Same author

Impact of diabetes on stage I lung cancer treatment patterns and prognosis in older adults: A population-based cohort study.

Heliyon·2023
Same author

Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent.

Frontiers in immunology·2023
Same author

Subjective social status, race, and metabolic syndrome in women with breast cancer.

Breast cancer research and treatment·2023
Same journal

Extracellular matrix reprogramming by the YAP/TAZ- TGF-ß2 axis drives immune exclusion in cholangiocarcinoma models.

The Journal of clinical investigation·2026
Same journal

Tumor cell-derived extracellular vesicles foster the immunosuppressive landscape of pancreatic cancer.

The Journal of clinical investigation·2026
Same journal

Julie Zikherman receives the ASCI/Marian W. Ropes, MD, Award.

The Journal of clinical investigation·2026
Same journal

Targeted degradation of MDM2 overcomes feedback regulation of p53 signaling in Merkel cell carcinoma models.

The Journal of clinical investigation·2026
Same journal

SGLT2 inhibitors enhance ketogenesis by acting as allosteric activators of the mitochondrial enzyme HMGCS2.

The Journal of clinical investigation·2026
Same journal

MDM2 degraders for Merkel cell carcinoma: round peg in a round hole.

The Journal of clinical investigation·2026
See all related articles

Suppressor of Cytokine Signaling 2 (SOCS2) negatively regulates growth hormone (GH) signaling. SOCS2-deficient mice exhibit gigantism, confirming its role in controlling growth.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Genetics

Background:

  • The growth hormone/IGF-1-signaling (GH/IGF-1-signaling) system is crucial for growth, development, and aging.
  • JAK/STAT pathways mediate GH signaling to the nucleus.

Discussion:

  • SOCS2 acts as a negative regulator of GH signaling.
  • SOCS2-knockout mice display gigantism, indicating its role in growth control.
  • This overgrowth phenotype is dependent on endogenous GH.

Key Insights:

  • SOCS2 deficiency leads to excessive growth.
  • GH administration to mice lacking both GH and SOCS2 results in pronounced overgrowth.
  • This highlights SOCS2's specific role in modulating GH's growth-promoting effects.

Related Experiment Videos

Outlook:

  • Further research into SOCS2 regulation can offer insights into growth disorders.
  • Understanding SOCS2's mechanism may reveal therapeutic targets for conditions related to growth and aging.